Public Health | December 11, 2021
Cipla aims to improve access to nebulisers in PHCs
The company will donate 5000 nebulizers to primary health care centres in rural India
The company will donate 5000 nebulizers to primary health care centres in rural India
The company is focused on the development of novel treatments for RNA viruses
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
An MoU was signed between B Medical Systems and Gujarat government recently
Subscribe To Our Newsletter & Stay Updated
